Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | IGF-1 LR3 | Mecasermin |
|---|---|---|
| Class | Experimental IGF-1 analogue | Recombinant IGF-1 |
| Research category | GH / IGF-1 axis | severe primary IGF-1 deficiency |
| Evidence level | Very low | High |
| Overall status | Not approved — research | Approved (Rx, FDA/EMA) — severe primary IGF-1 deficiency |
| FDA | Not approved | Approved (Rx) |
| EMA | Not approved | Approved (Rx) |
| WADA | Prohibited — S2 | Prohibited — S2 |
| Mechanism studied | IGF-1 LR3 → Reduced IGFBP binding → IGF-1 receptor → PI3K–Akt / MAPK | Mecasermin → IGF-1 receptor → Growth-plate signalling → Linear growth |
| Molecular weight | 9,111 g/mol | — |
| Sizes in stock | 1mg | Not currently listed |
Where the research overlaps
Both compounds are studied within GH Axis research. IGF-1 LR3 is classed as experimental igf-1 analogue, while Mecasermin is recombinant igf-1. Evidence is rated very low for IGF-1 LR3 and high for Mecasermin.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.